Open AccessAddition of docetaxel or abiraterone to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer in Indian population
Author(s) -
Alok Gupta,
Shaik Maheboob Hussain,
Neha Sonthwal,
Harit Chaturvedi
Publication year - 2021
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_342_19
Subject(s) - docetaxel , prostate cancer , medicine , androgen deprivation therapy , abiraterone , oncology , population , urology , cancer , androgen receptor , environmental health
The addition of docetaxel or abiraterone to androgen deprivation therapy (ADT) achieves superior survival outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) in predominantly Western population. We sought to evaluate the treatment outcomes of adding docetaxel or abiraterone to ADT in Indian population.